Report cover image

Europe Constrained Peptide Drugs Market: Analysis and Forecast, 2024-2040

Publisher BIS Research
Published Jan 31, 2024
Length 84 Pages
SKU # BIS18466638

Description

Europe Constrained Peptide Drugs Market: Analysis and Forecast, 2024-2040


Introduction to Europe constrained peptide drugs market

The market size is anticipated to be $0.06 billion in 2026 and is expected to reach $7.72 billion by 2040, growing at a CAGR of 41.55% during the forecast period 2026-2040. The constrained peptide drugs market is expected to experience significant growth, driven by innovative constrained peptide pipelines that now target more than just receptors. Advances in chemical technologies, the success of synthetic peptides in therapeutics, and their affordability across various diseases are also contributing to the projected growth in the forecast period.

Market Introduction

The Europe constrained peptide drugs market is poised for substantial growth in the coming years. One of the key drivers of this expansion is the region's robust pharmaceutical industry, characterized by a focus on research and development, innovation, and a strong regulatory framework. European pharmaceutical companies have been at the forefront of developing constrained peptide drugs, leveraging cutting-edge technologies and expertise in peptide chemistry.

Additionally, Europe has witnessed a growing demand for novel therapeutic approaches, particularly in the treatment of various diseases such as cancer, autoimmune disorders, and metabolic conditions. Constrained peptides offer a promising solution due to their specificity and potential for enhanced efficacy and safety profiles.

Furthermore, collaborative efforts between academia, research institutions, and pharmaceutical companies in Europe have accelerated the discovery and development of constrained peptide-based therapeutics. This collaborative ecosystem fosters innovation and positions Europe as a significant player in the constrained peptide drugs market.

Market Segmentation

Segmentation 1: by Country

Germany
U.K.
France
Italy
Spain

Segmentation 2: by Company

Bicycle Therapeutics plc
Spexis AG
Santhera Pharmaceuticals
Union Chimique Belge S.A. (UCB)
Biosynth (Pepscan)
Zealand Pharma

How can this report add value to an organization?

Workflow/Innovation Strategy: Over the past decade, peptide drug discovery and development has witnessed a renaissance and scientific thrust as the industry has come to acknowledge the capability of peptide therapeutics in addressing unmet medical needs and the potential of this class of molecules to become a significant accompaniment or even favored alternative treatment to biologics and small molecules.

Peptide therapeutics have demonstrated a novel and selective yet safe mode of action for a wide range of indications. The existing and future development of constrained peptide drugs will continue to burgeon upon the strengths of constrained peptides and innovative technologies employed in the discovery and development, including peptide drug conjugates, multifunctional peptides, and cell-penetrating peptides. Furthermore, limitations associated with presently available peptides have resulted in an urgent need for new design, administration, and synthesis in peptide therapeutics, thereby leading to advancements in the development of constrained peptides.

Growth/Marketing Strategy: Constrained peptides provide noteworthy advantages over linear peptides. An increase in interest in constrained peptides due to their properties led to advancements in peptide synthesis technologies.

Competitive Strategy: Key players in the Europe constrained peptide drugs market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe constrained peptide drugs market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 1-5 business days to complete the report upon order confirmation.

Table of Contents

84 Pages
Executive Summary
1 Definition
1.1 Inclusion and Exclusion Criteria
2 Research Scope
2.1 Key Questions Answered in the Report
3 Research Methodology
3.1 Constrained Peptides: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 Markets Overview
4.1 Introduction
4.1.1 Structure and Design of Constrained Peptides
4.1.2 Types of Constrained Peptides
4.2 Evolution of Constrained Peptides
4.3 Development of Constrained Peptides as Drugs
4.4 Potential Therapy Areas
4.5 Value Chain-Key Stakeholders
4.6 Key Industry Trends (by Region)
4.7 Key Industry Trends by Route of Administration
4.8 Key Industry Trends-Technological Advancements
4.9 Current Market Size and Growth Potential, $Billion, 2024-2040
4.1 COVID-19 Impact on Constrained Peptides Drugs Market
4.10.1 Impact on Constrained Peptide Drugs Companies
4.10.2 Clinical Trial Disruptions and Resumptions
5 Europe
5.1 Constrained Peptide Drugs Market (by Country), $Billion, 2024-2031
5.1.1 Europe
5.1.1.1 U.K.
5.1.1.2 Germany
5.1.1.3 France
5.1.1.4 Italy
5.1.1.5 Spain
6 Company Profiles
6.1 Overview
6.2 Bicycle Therapeutics plc
6.2.1 Company Overview
6.2.2 Role of Bicycle Therapeutics plc in the Constrained Peptide Drugs Market
6.2.1 Current Status and Policies for Investigational Drugs
6.2.2 Key Competitors of the Company
6.2.3 Financials
6.2.4 Key Insights about the Financial Health of the Company
6.2.5 Corporate Strategies
6.2.5.1 Synergistic Activities
6.2.5.2 Funding
6.2.6 Business Strategies
6.2.6.1 Clinical Developments
6.2.6.2 Regulatory and Legal
6.2.7 Analyst Perspective
6.3 Spexis AG
6.3.1 Company Overview
6.3.2 Role of Spexis AG in the Constrained Peptide Drugs Market
6.3.3 Current Status and Policies for Investigational Drugs
6.3.4 Key Competitors of the Company
6.3.5 Financials
6.3.6 Key Insights about the Financial Health of the Company
6.3.7 Corporate Strategies
6.3.7.1 Funding
6.3.7.2 Mergers and Acquisitions
6.3.7.3 Synergistic activities
6.3.8 Business Strategies
6.3.8.1 Regulatory and Legal
6.3.9 Analyst Perspective
6.4 Santhera Pharmaceuticals
6.4.1 Company Overview
6.4.2 Role of Santhera Pharmaceuticals in the Constrained Peptide Drugs Market
6.4.3 Current Status and Policies for Investigational Drugs
6.4.4 Key Competitors of the Company
6.4.5 Financials
6.4.6 Corporate Strategies
6.4.6.1 Funding
6.4.7 Business Strategies
6.4.7.1 Clinical Developments
6.4.8 Analyst Perspective
6.5 Union Chimique Belge S.A. (UCB)
6.5.1 Company Overview
6.5.2 Role of Union Chimique Belge S.A. (UCB) in the Constrained Peptide Drugs Market
6.5.3 Current Status and Policies for Investigational Drugs
6.5.4 Key Competitors of the Company
6.5.5 Financials
6.5.6 Key Insights about the Financial Health of the Company
6.5.7 Corporate Strategies
6.5.7.1 Mergers and Acquisitions
6.5.8 Business Strategies
6.5.8.1 Clinical Developments
6.5.8.2 Regulatory and legal
6.5.9 Analyst Perspective
6.6 Biosynth (Pepscan)
6.6.1 Company Overview
6.6.2 Role of Biosynth (Pepscan) in the Constrained Peptide Drugs Market
6.6.3 Key Competitors of the Company
6.6.4 Corporate Strategies
6.6.4.1 License
6.6.5 Business Strategies
6.6.5.1 Product Launch
6.6.6 Analyst Perspective
6.6.7 Zealand Pharma
6.6.7.1 ZP10000 (Preclinical)
6.6.7.1.1 Product Profile
List of Figures
Figure 1: Europe Total Number of Drugs Approved by the U.S. FDA, 2016-2021
Figure 2: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 3: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 4: Europe Constrained Peptide Drugs: Impact Analysis
Figure 5: Constrained Peptide Drugs Market (by Region), $Billion, 2024-2040
Figure 6: Constrained Peptide Drugs Methodology
Figure 7: Primary Research Methodology
Figure 8: Epidemiology-Based Approach
Figure 9: Inducing Conformational Effects
Figure 10: Two Main Types of Constraints
Figure 11: Methodology for Restricting Conformation in Peptides
Figure 12: Types of Constrained Peptides
Figure 13: Key Milestones in the Evolution of Constrained Peptides
Figure 14: Major Factors Affecting Constrained Peptide Development
Figure 15: Value Chain Analysis- Key Stakeholders
Figure 16: Constrained Peptide Drugs Market (by Region), $Billion, 2024-2031
Figure 17: Constrained Peptide Drugs Market (by Region), $Billion, 2032-2040
Figure 18: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 19: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 20: Constrained Peptide Drugs Market (by Region)
Figure 21: Constrained Peptide Drugs Market (by Region), $Billion, 2024-2040
Figure 22: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 23: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 24: Europe: Market Dynamics
Figure 25: Europe Constrained Peptide Drugs Market (by Country), $Billion, 2025 and 2040
Figure 26: U.K. Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 27: U.K. Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 28: Germany Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 29: Germany Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 30: France Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 31: France Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 32: Italy Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 33: Italy Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 34: Spain Constrained Peptide Drugs Market, $Billion, 2024-2031
Figure 35: Spain Constrained Peptide Drugs Market, $Billion, 2032-2040
Figure 36: Total Number of Companies Profiled
Figure 37: Bicycle Therapeutics plc: Product Portfolio
Figure 38: Bicycle Therapeutics plc: Overall Financials, $Million, 2019-2021
Figure 39: Bicycle Therapeutics plc: Revenue (by Region), $Million, 2019-2021
Figure 40: Bicycle Therapeutics plc: R&D Expenditure, $Million, 2019-2021
Figure 41: Spexis AG: Product Portfolio
Figure 42: Spexis AG: Overall Financials, $Million, 2019-2021
Figure 43: Spexis AG: R&D Expenditure, $Million, 2019-2021
Figure 44: Santhera Pharmaceuticals: Product Portfolio
Figure 45: Santhera Pharmaceuticals: Overall Financials, $Million, 2019-2021
Figure 46: Union Chimique Belge S.A. (UCB): Product Portfolio
Figure 47: Union Chimique Belge S.A. (UCB): Overall Financials, $Million, 2019-2021
Figure 48: Union Chimique Belge S.A. (UCB): R&D Expenditure, $Million, 2019-2021
Figure 49: Biosynth (Pepscan): Product Portfolio
List of Tables
Table 1: Potential Indications of Constrained Peptide Drugs
Table 2: Potential Therapy Areas of Constrained Peptide Drugs
Table 3: Route of Administration of Constrained Peptide Drugs
Table 4: Impact of COVID-19 on Constrained Peptide Drug Companies

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us